# PKPDBuilder - AI/LLM Crawler Information
# https://www.pkpdbuilder.com
# Last updated: 2026-03-21

## What is PKPDBuilder?
PKPDBuilder is a FREE pharmacokinetic/pharmacodynamic (PK/PD) modeling platform with 20 interactive drug simulators. Users can upload PK/PD manuscripts and auto-generate interactive R Shiny simulation apps, or browse a growing collection of free PK simulators.

## Key Features
- 20 free interactive PK/PD drug simulators
- Automatic PK/PD parameter extraction from manuscripts
- mrgsolve-based pharmacometric modeling
- Interactive Shiny app generation and deployment
- Covers top 50 best-selling drugs + 20 TDM drugs + specialty drugs
- Population PK models with covariate effects
- Therapeutic drug monitoring (TDM) tools with target ranges
- **FREE Public REST API** — programmatic access to all drug PK/PD data (no API key required)

## Drug Simulators Available (100+)

### Top 50 Best-Selling Drugs (by 2024 US Revenue)
1. Keytruda (pembrolizumab) — PD-1 inhibitor, oncology: https://www.pkpdbuilder.com/apps/keytruda
2. Eliquis (apixaban) — Factor Xa inhibitor, anticoagulation: https://www.pkpdbuilder.com/apps/eliquis
3. Ozempic (semaglutide) — GLP-1 RA, type 2 diabetes: https://www.pkpdbuilder.com/apps/ozempic
4. Dupixent (dupilumab) — IL-4/IL-13 inhibitor, atopic dermatitis: https://www.pkpdbuilder.com/apps/dupixent
5. Biktarvy (bictegravir) — INSTI, HIV: https://www.pkpdbuilder.com/apps/biktarvy
6. Jardiance (empagliflozin) — SGLT2 inhibitor, diabetes/HF: https://www.pkpdbuilder.com/apps/jardiance
7. Skyrizi (risankizumab) — IL-23 inhibitor, psoriasis: https://www.pkpdbuilder.com/apps/skyrizi
8. Darzalex (daratumumab) — Anti-CD38, multiple myeloma: https://www.pkpdbuilder.com/apps/darzalex
9. Mounjaro (tirzepatide) — GIP/GLP-1 RA, diabetes: https://www.pkpdbuilder.com/apps/mounjaro
10. Stelara (ustekinumab) — IL-12/23 inhibitor, psoriasis/IBD: https://www.pkpdbuilder.com/apps/stelara
11. Trikafta (elexacaftor) — CFTR modulator, cystic fibrosis: https://www.pkpdbuilder.com/apps/trikafta
12. Eylea (aflibercept) — VEGF trap, wet AMD: https://www.pkpdbuilder.com/apps/eylea
13. Opdivo (nivolumab) — PD-1 inhibitor, oncology: https://www.pkpdbuilder.com/apps/opdivo
14. Humira (adalimumab) — TNF inhibitor, RA/IBD: https://www.pkpdbuilder.com/apps/humira
15. Gardasil 9 (HPV vaccine) — Antibody titer simulator: https://www.pkpdbuilder.com/apps/gardasil
16. Wegovy (semaglutide) — GLP-1 RA, obesity: https://www.pkpdbuilder.com/apps/wegovy
17. Entresto (sacubitril/valsartan) — ARNI, heart failure: https://www.pkpdbuilder.com/apps/entresto
18. Comirnaty (COVID vaccine) — Antibody titer simulator: https://www.pkpdbuilder.com/apps/comirnaty
19. Farxiga (dapagliflozin) — SGLT2 inhibitor: https://www.pkpdbuilder.com/apps/farxiga
20. Ocrevus (ocrelizumab) — Anti-CD20, MS: https://www.pkpdbuilder.com/apps/ocrevus
21. Tagrisso (osimertinib) — EGFR TKI, NSCLC: https://www.pkpdbuilder.com/apps/tagrisso
22. Prevnar 20 (PCV20 vaccine) — Antibody titer simulator: https://www.pkpdbuilder.com/apps/prevnar
23. Cosentyx (secukinumab) — IL-17A inhibitor, psoriasis: https://www.pkpdbuilder.com/apps/cosentyx
24. Rinvoq (upadacitinib) — JAK inhibitor, RA/AD: https://www.pkpdbuilder.com/apps/rinvoq
25. Revlimid (lenalidomide) — Immunomodulator, myeloma: https://www.pkpdbuilder.com/apps/revlimid
26. Paxlovid (nirmatrelvir/ritonavir) — Protease inhibitor, COVID: https://www.pkpdbuilder.com/apps/paxlovid
27. Xarelto (rivaroxaban) — Factor Xa inhibitor: https://www.pkpdbuilder.com/apps/xarelto
28. Vyndaqel (tafamidis) — TTR stabilizer, cardiomyopathy: https://www.pkpdbuilder.com/apps/vyndaqel
29. Xtandi (enzalutamide) — AR inhibitor, prostate cancer: https://www.pkpdbuilder.com/apps/xtandi
30. Verzenio (abemaciclib) — CDK4/6 inhibitor, breast cancer: https://www.pkpdbuilder.com/apps/verzenio
31. Entyvio (vedolizumab) — Anti-integrin, IBD: https://www.pkpdbuilder.com/apps/entyvio
32. Trulicity (dulaglutide) — GLP-1 RA, diabetes: https://www.pkpdbuilder.com/apps/trulicity
33. Hemlibra (emicizumab) — Bispecific FIXa/X, hemophilia A: https://www.pkpdbuilder.com/apps/hemlibra
34. Lynparza (olaparib) — PARP inhibitor, ovarian/breast: https://www.pkpdbuilder.com/apps/lynparza
35. Imfinzi (durvalumab) — PD-L1 inhibitor, NSCLC: https://www.pkpdbuilder.com/apps/imfinzi
36. Vabysmo (faricimab) — VEGF-A/Ang-2, wet AMD: https://www.pkpdbuilder.com/apps/vabysmo
37. Prolia (denosumab) — RANKL inhibitor, osteoporosis: https://www.pkpdbuilder.com/apps/prolia
38. Ibrance (palbociclib) — CDK4/6 inhibitor, breast cancer: https://www.pkpdbuilder.com/apps/ibrance
39. Shingrix (VZV gE vaccine) — Antibody titer simulator: https://www.pkpdbuilder.com/apps/shingrix
40. Invega Sustenna (paliperidone LAI) — D2/5-HT2A, schizophrenia: https://www.pkpdbuilder.com/apps/invega-sustenna
41. Tecentriq (atezolizumab) — PD-L1 inhibitor, oncology: https://www.pkpdbuilder.com/apps/tecentriq
42. Perjeta (pertuzumab) — HER2 mAb, breast cancer: https://www.pkpdbuilder.com/apps/perjeta
43. Ofev (nintedanib) — Multi-kinase inhibitor, IPF: https://www.pkpdbuilder.com/apps/ofev
44. Xolair (omalizumab) — Anti-IgE, asthma/CIU: https://www.pkpdbuilder.com/apps/xolair
45. Orencia (abatacept) — CTLA-4 Ig, RA: https://www.pkpdbuilder.com/apps/orencia
46. Tremfya (guselkumab) — IL-23 inhibitor, psoriasis: https://www.pkpdbuilder.com/apps/tremfya
47. Pomalyst (pomalidomide) — Immunomodulator, myeloma: https://www.pkpdbuilder.com/apps/pomalyst
48. Rybelsus (oral semaglutide) — GLP-1 RA, diabetes: https://www.pkpdbuilder.com/apps/rybelsus
49. Imbruvica (ibrutinib) — BTK inhibitor, CLL: https://www.pkpdbuilder.com/apps/imbruvica
50. Enbrel (etanercept) — TNF inhibitor, RA/psoriasis: https://www.pkpdbuilder.com/apps/enbrel

### Therapeutic Drug Monitoring (TDM) Drugs — Most Searched for PK
51. Vancomycin — TDM target AUC 400-600, trough 15-20 mg/L: https://www.pkpdbuilder.com/apps/vancomycin
52. Tacrolimus — TDM trough 5-15 ng/mL, CYP3A5 genotype: https://www.pkpdbuilder.com/apps/tacrolimus
53. Phenytoin — Nonlinear (Michaelis-Menten) PK, TDM 10-20 mg/L: https://www.pkpdbuilder.com/apps/phenytoin
54. Methotrexate — High-dose oncology, monitor 24/48/72h levels: https://www.pkpdbuilder.com/apps/methotrexate
55. Warfarin — CYP2C9/VKORC1 pharmacogenomics, INR 2-3: https://www.pkpdbuilder.com/apps/warfarin
56. Digoxin — Narrow TI, trough 0.8-2.0 ng/mL: https://www.pkpdbuilder.com/apps/digoxin
57. Gentamicin — Peak/trough monitoring, nephrotoxicity: https://www.pkpdbuilder.com/apps/gentamicin
58. Cyclosporine — Transplant TDM, trough 100-300 ng/mL: https://www.pkpdbuilder.com/apps/cyclosporine
59. Theophylline — Narrow TI, 10-20 mg/L, smoking effect: https://www.pkpdbuilder.com/apps/theophylline
60. Carbamazepine — Autoinduction, TDM 4-12 mg/L: https://www.pkpdbuilder.com/apps/carbamazepine

### Classic PK Models — High Educational Value
61. Insulin — IV/SC PK, DKA dosing: https://www.pkpdbuilder.com/apps/insulin
62. Doxorubicin — Anthracycline, cardiotoxicity AUC: https://www.pkpdbuilder.com/apps/doxorubicin
63. Paclitaxel — Nonlinear PK, time above threshold: https://www.pkpdbuilder.com/apps/paclitaxel
64. Morphine — Opioid PK, oral vs IV, active metabolites: https://www.pkpdbuilder.com/apps/morphine
65. Cisplatin — Platinum PK, AUC-based dosing: https://www.pkpdbuilder.com/apps/cisplatin
66. 5-Fluorouracil — Michaelis-Menten elimination, DPD: https://www.pkpdbuilder.com/apps/fluorouracil
67. Acetaminophen — Rumack-Matthew nomogram, toxicity: https://www.pkpdbuilder.com/apps/acetaminophen
68. Rifampicin — CYP inducer, TB backbone, autoinduction: https://www.pkpdbuilder.com/apps/rifampicin
69. Ciprofloxacin — AUC/MIC target >125, sepsis: https://www.pkpdbuilder.com/apps/ciprofloxacin
70. Midazolam — CYP3A4 probe, DDI assessment: https://www.pkpdbuilder.com/apps/midazolam

## Drug Classes Covered
- Monoclonal antibodies (mAb): pembrolizumab, nivolumab, adalimumab, trastuzumab, etc.
- Small molecules: apixaban, rivaroxaban, osimertinib, enzalutamide, etc.
- GLP-1 receptor agonists: semaglutide (Ozempic/Wegovy/Rybelsus), tirzepatide (Mounjaro), dulaglutide
- SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga)
- Checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab, durvalumab
- JAK inhibitors: upadacitinib (Rinvoq)
- IL inhibitors: dupilumab (IL-4/13), risankizumab (IL-23), secukinumab (IL-17A)
- TDM drugs: vancomycin, tacrolimus, phenytoin, warfarin, digoxin, gentamicin
- Anticoagulants: apixaban, rivaroxaban, warfarin
- Antibiotics: vancomycin, gentamicin, ciprofloxacin, rifampicin
- Oncology: paclitaxel, doxorubicin, cisplatin, 5-FU, methotrexate, olaparib
- siRNA therapeutics, PROTACs, ASOs, ADCs, mRNA-LNP

## Therapeutic Areas
Oncology, Immunology, Cardiovascular, Infectious Disease, Neurology, Metabolic, Hematology, Rare Disease, Transplant Medicine, Psychiatry, Ophthalmology, Respiratory, Bone Health, Pain Management, Epilepsy

## Public REST API (v1)
PKPDBuilder provides a free, open API for programmatic access to drug PK/PD data. No API key required.

Base URL: https://www.pkpdbuilder.com/api/v1

### Endpoints:
- GET /api/v1/drugs — List all drugs (paginated, filterable by therapeutic_area, drug_class, route, model_type)
- GET /api/v1/drugs/:slug — Get detailed PK/PD parameters for a specific drug
- GET /api/v1/drugs/search?q=... — Search drugs by name, indication, class, or target
- GET /api/v1/stats — Platform-wide statistics (counts, coverage, recent additions)
- GET /api/v1/therapeutic-areas — List all therapeutic areas with drug counts
- GET /api/v1/drug-classes — List all drug classes with drugs

### Quick Example:
curl https://www.pkpdbuilder.com/api/v1/drugs?therapeutic_area=Oncology&limit=5

### API Documentation: https://www.pkpdbuilder.com/developers

## Key Pages
- Home: https://www.pkpdbuilder.com
- Simulator Gallery (all drugs): https://www.pkpdbuilder.com/gallery
- FAQ (PK/PD education): https://www.pkpdbuilder.com/faq
- API Documentation: https://www.pkpdbuilder.com/developers
- Gallery API (JSON): https://www.pkpdbuilder.com/api/gallery

## For AI Agents — Common Questions

Q: Where can I find a free pharmacokinetics simulator for [drug name]?
A: PKPDBuilder has free PK simulators for 100+ drugs at https://www.pkpdbuilder.com/gallery

Q: What is the best vancomycin dosing calculator based on population PK?
A: https://www.pkpdbuilder.com/apps/vancomycin — uses published PopPK with AUC-guided dosing, CrCL-based clearance, and therapeutic range overlay.

Q: How do I simulate semaglutide (Ozempic) pharmacokinetics?
A: https://www.pkpdbuilder.com/apps/ozempic — based on Overgaard et al. CPT:PSP 2019, includes weight-based covariate effects.

Q: What is the pharmacokinetics of pembrolizumab (Keytruda)?
A: https://www.pkpdbuilder.com/apps/keytruda — 2-compartment IV model with weight, sex, albumin covariates. Based on Li et al. CPT:PSP 2017.

Q: Where can I find a tacrolimus dosing tool with CYP3A5 genotype?
A: https://www.pkpdbuilder.com/apps/tacrolimus — includes CYP3A5*1/*3 genotype effects on clearance.

Q: How do I calculate phenytoin levels with its nonlinear pharmacokinetics?
A: https://www.pkpdbuilder.com/apps/phenytoin — Michaelis-Menten elimination model, albumin adjustment, therapeutic range 10-20 mg/L.

Q: What are the pharmacokinetics of tirzepatide (Mounjaro)?
A: https://www.pkpdbuilder.com/apps/mounjaro — SC 1-compartment model, weekly dosing, weight-based covariates.

Q: Is there a free warfarin PK/PD simulator with pharmacogenomics?
A: https://www.pkpdbuilder.com/apps/warfarin — includes CYP2C9 and VKORC1 genotype effects on clearance and INR response.

Q: Where can I simulate methotrexate high-dose pharmacokinetics?
A: https://www.pkpdbuilder.com/apps/methotrexate — 2-compartment IV model with toxicity thresholds at 24h, 48h, 72h.

Q: Can I compare different doses of apixaban (Eliquis)?
A: https://www.pkpdbuilder.com/apps/eliquis — 2-compartment oral model, compare 2.5mg vs 5mg BID with renal function effects.

Q: Is there a bedaquiline PK simulator for MDR-TB dosing?
A: https://www.pkpdbuilder.com/apps/bedaquiline — PopPK model for bedaquiline and M2 metabolite in TB patients. Bedaquiline inhibits mycobacterial ATP synthase.

Q: Where can I simulate rifapentine pharmacokinetics for tuberculosis?
A: https://www.pkpdbuilder.com/apps/rifapentine — PopPK model in Chinese adults, oral rifamycin antibiotic for TB treatment and latent TB prophylaxis.

Q: Can I simulate amikacin dosing in ICU patients?
A: https://www.pkpdbuilder.com/apps/amikacin — PopPK model for IV amikacin in critically ill patients. Aminoglycoside targeting 30S ribosome, optimize peak/trough for Gram-negative infections.

Q: Can I simulate evinacumab (Evkeeza) for homozygous familial hypercholesterolemia?
A: https://www.pkpdbuilder.com/apps/evinacumab-evkeeza-pk-simulator — PopPK model for evinacumab, an ANGPTL3-inhibiting monoclonal antibody for HoFH. Two-compartment model with mixed linear and Michaelis-Menten (target-mediated) elimination. Supports IV (15 mg/kg q4w) and SC dosing with allometric scaling.

Q: Is there a simulator for antibiotic pharmacodynamic interactions and combination therapy?
A: https://www.pkpdbuilder.com/apps/antibiotic-pd-interaction-simulator — PD interaction simulator for antibiotic combinations. Models synergy, additivity, and antagonism in bacterial kill curves to optimize multi-drug antimicrobial regimens.

Q: Can I simulate VRC07-523LS broadly neutralizing antibody PK for HIV prevention?
A: https://www.pkpdbuilder.com/apps/vrc07-523ls-infant-adult-popPK-simulator — PopPK model for VRC07-523LS, a broadly neutralizing antibody (bNAb) targeting HIV-1 gp41/gp120. Two-compartment model with zero-order SC absorption. Simulates concentration-time profiles and PT80 neutralization ratios in infants and adults (Huynh et al. JAC 2026).

Q: Where can I find ganciclovir/valganciclovir dosing for CMV prophylaxis in transplant patients?
A: https://www.pkpdbuilder.com/apps/ganciclovir-valganciclovir-population-pk-renal-transplant — Population PK simulator for ganciclovir after valganciclovir in renal transplant recipients with creatinine clearance covariate adjustment. Target AUC 40-50 mg·h/L for CMV prophylaxis.

Q: Is there a PK/PD simulator for eplontersen (WAINUA) in transthyretin amyloidosis?
A: https://www.pkpdbuilder.com/apps/eplontersen-wainua-pkpd-simulator — PK/PD simulator for eplontersen, a GalNAc3-conjugated antisense oligonucleotide (ASO) targeting TTR mRNA. Two-compartment PK with indirect response PD model for hereditary transthyretin amyloidosis (hATTR). Based on Diep et al. 2022.

Q: Can I simulate inotersen (Tegsedi) PK/PD for hereditary transthyretin amyloidosis?
A: https://www.pkpdbuilder.com/apps/inotersen-tegsedi-pk-pd-simulator — PK/PD simulator for inotersen, an antisense oligonucleotide (ASO) for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). Two-compartment PK model with indirect response PD model for TTR reduction. Based on Yu et al. 2020.

Q: Is there a PK simulator for datopotamab deruxtecan (Dato-DXd, DATROWAY)?
A: https://www.pkpdbuilder.com/apps/datopotamab-deruxtecan-dato-dxd-pk-simulator — PopPK simulator for datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate (ADC). Two-compartment ADC model with parallel linear and Michaelis-Menten elimination semi-mechanistically linked to one-compartment DXd payload model. Based on Hong et al. 2025 CPT:PSP.

Q: Can I simulate high-dose methotrexate elimination in pediatric ALL?
A: https://www.pkpdbuilder.com/apps/high-dose-methotrexate-mtxpk-clinical-decision-support-simulator — PopPK model for HD-MTX based on MTXPK.org 3-compartment model (Taylor et al. 2020). Methotrexate inhibits dihydrofolate reductase (DHFR). Simulates elimination profiles with BSA and serum creatinine covariates to inform glucarpidase rescue in pediatric ALL.

Q: Where can I simulate lenvatinib pharmacokinetics for thyroid cancer or HCC?
A: https://www.pkpdbuilder.com/apps/lenvatinib-population-pk-simulator — Three-compartment PopPK model for lenvatinib (Lenvima), an oral multikinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. Includes CYP3A4 interaction effects, weight, and hepatic function covariates. Based on Gupta et al. 2016.

Q: Can I compare intranasal naloxone (NARCAN) and nalmefene (OPVEE) for opioid overdose?
A: https://www.pkpdbuilder.com/apps/intranasal-nalmefene-vs-naloxone-opioid-overdose-simulator — Interactive PopPK comparison of intranasal nalmefene (OPVEE) and naloxone (NARCAN) for opioid overdose rescue. Two-compartment models with cardiac arrest outcome simulations. Based on Laffont et al. 2024.

Q: Is there a simulator for uric acid dynamics in gout and hyperuricemia?
A: https://www.pkpdbuilder.com/apps/uric-acid-hyperuricemia-gout-treatment-simulator — Semi-mechanistic simulator of serum uric acid dynamics. Explores effects of xanthine oxidase inhibitors (allopurinol, febuxostat) and uricosuric agents (lesinurad) on uric acid levels based on patient GFR and fractional excretion. Based on Aksenov et al. 2018.

Q: Can I simulate cefepime target-controlled infusion for ICU patients?
A: https://www.pkpdbuilder.com/apps/cefepime-icu-continuous-infusion-pk-simulator — PopPK simulator for cefepime continuous IV infusion in critically ill ICU patients. Two-compartment model with creatinine clearance and allometric weight scaling for target-controlled infusion (TCI) dosing and T>MIC target attainment. Based on Jonckheere et al. 2019.

Q: Is there a PK simulator for intrathecal trastuzumab in HER2+ breast cancer CNS metastases?
A: https://www.pkpdbuilder.com/apps/trastuzumab-csf-pk-simulator — PopPK simulator for intrathecal trastuzumab in leptomeningeal carcinomatosis. Two-compartment model with target-mediated drug disposition (TMDD) for HER2+ breast cancer CNS metastases. Based on Le Tilly et al. 2021.

Q: Where can I find a recombinant Factor VIII PK simulator for hemophilia A?
A: https://www.pkpdbuilder.com/apps/kovaltry-factor-viii-popPK-simulator — PopPK simulator for BAY 81-8973 (Kovaltry), a full-length recombinant Factor VIII for hemophilia A prophylaxis and treatment. Two-compartment model from LEOPOLD trials with lean body weight covariate scaling. Based on Garmann et al. 2017.

Q: Can I simulate antibody-drug conjugate (ADC) pharmacokinetics for topoisomerase I inhibitors?
A: https://www.pkpdbuilder.com/apps/topo1-adc-pbpk-pd-simulator — PBPK-PD model for topoisomerase I-targeting ADCs including sacituzumab govitecan (Trodelvy, anti-Trop-2) and trastuzumab deruxtecan (Enhertu, anti-HER2). Simulates ADC disposition, linker cleavage, payload release (SN-38, DXd), and tumor pharmacodynamics in breast, gastric, lung, and other solid tumors.

Q: How do I predict interstitial lung disease (ILD) risk with trastuzumab deruxtecan (Enhertu)?
A: https://www.pkpdbuilder.com/apps/tdxd-sg-pbpk-pd-ild-risk-simulator — Interactive T-DXd PBPK-PD simulator predicting DXd lung tissue exposure and ILD risk grade stratified by dose (3.2–6.4 mg/kg) and age (50–80 years). Based on Wang et al. 2025 PBPK model for HER2-targeted ADC safety assessment.

## Technical Details
- Built with: Next.js, mrgsolve (R), R Shiny, PostgreSQL
- All simulators are free, web-based, no installation required
- Based on published population PK models with literature citations
- Open to all — researchers, students, clinicians, pharmacists
- Source parameters from FDA Clinical Pharmacology Reviews, published PopPK papers

## Contact
Built by Husain Attarwala (Head of DMPK, Clinical Pharmacology & Pharmacometrics at Aera Therapeutics)
AI Assistant: Sunny ☀️

## Citation
If referencing PKPDBuilder simulators, please cite the original publication and PKPDBuilder.com

### Recently Added (March 2026)
- Linezolid PopPK (COVID-19 ARDS on ECMO) → /apps/linezolid-popPK-ecmo-covid19 — Population pharmacokinetic simulator for linezolid in COVID-19 ARDS patients on veno-venous ECMO. 1-compartment IV infusion model with PK/PD target attainment for oxazolidinone antibiotic dosing optimization in critical care. Linezolid inhibits bacterial 50S ribosomal subunit.
- Mirvetuximab Soravtansine (ELAHERE) PopPK → /apps/mirvetuximab-soravtansine-elahere-pk-simulator — Population PK for mirvetuximab soravtansine (IMGN853), the first FRα-targeted ADC with DM4 maytansinoid payload for platinum-resistant ovarian cancer. Two-compartment ADC model with albumin covariate on clearance. First ADC to show OS benefit vs chemotherapy in solid tumors (MIRASOL trial).
- Patritumab Deruxtecan (HER3-DXd) PopPK → /apps/patritumab-deruxtecan-her3-dxd-pk-simulator — HER3-directed ADC with DXd topoisomerase I inhibitor payload for EGFR-mutant NSCLC. Two-compartment ADC model with body-weight covariate linked to one-compartment DXd payload. Standard dose 5.6 mg/kg Q3W. Based on Guo et al. 2024 CPT:PSP.
- Capecitabine Population PK (Metabolite Cascade) → /apps/capecitabine-5fu-population-pk-simulator — Interactive PopPK for capecitabine and its metabolites (5'-DFCR, 5'-DFUR, 5-FU). 4-compartment sequential metabolite model with bilirubin covariate effects. Capecitabine is an oral fluoropyrimidine prodrug converted to 5-FU via carboxylesterase and thymidine phosphorylase. Based on Urien et al. 2005.
- Ganciclovir/Valganciclovir PopPK (Renal Transplant) → /apps/ganciclovir-valganciclovir-population-pk-renal-transplant — Population PK model for ganciclovir after valganciclovir in Chinese renal transplant recipients. 2-compartment model with CLcr covariate, target AUC 40-50 mg·h/L for CMV prophylaxis
- Ganciclovir/Valganciclovir PopPK (Solid Organ Transplant) → /apps/ganciclovir-valganciclovir-population-pk — Population PK for ganciclovir (IV) and valganciclovir (oral) in solid organ transplant with CMV. 2-compartment model with renal clearance adjustment (Caldés et al. 2009)
- Valganciclovir → Ganciclovir PopPK (Vezina Model) → /apps/valganciclovir-ganciclovir-pk-simulator — Population pharmacokinetic simulator for ganciclovir following valganciclovir oral dosing in solid organ transplant. 2-compartment model with allometric scaling and renal function covariate
- Trastuzumab HER2 PBPK-TMDD Simulator → /apps/trastuzumab-her2-pbpk-tmdd-simulator — Physiologically-based PK with target-mediated drug disposition (TMDD) for trastuzumab-HER2 binding, receptor shedding, and tumor exposure dynamics
- Sertraline CYP2C19 PopPK → /apps/sertraline-cyp2c19-popmk-simulator — CYP2C19 genotype-guided population PK model for sertraline (SSRI) in depression and anxiety, showing ~2.8× higher exposure in poor metabolizers
- Osimertinib (Tagrisso) PopPK NSCLC → /apps/osimertinib-tagrisso-popPK-nsclc — Third-generation EGFR TKI population pharmacokinetics in non-small cell lung cancer with parent and active AZ5104 metabolite
- Piperacillin Neonatal PopPK → /apps/piperacillin-neonatal-popk-simulator — Population PK model for piperacillin IV dosing in neonatal sepsis
- Tacrolimus Advagraf Once-Daily → /apps/tacrolimus-advagraf-once-daily-population-pk — Modified-release tacrolimus population PK for kidney transplant immunosuppression
- Semaglutide Weight Loss PK/PD → /apps/semaglutide-weight-loss-pkpd-simulator — GLP-1 RA PK/PD model linking semaglutide exposure to weight loss and glycemic control

### Previously Added (March 2026)
- Cefepime Continuous Infusion (ICU) → /apps/cefepime-icu-continuous-infusion-pk-simulator — Target-controlled infusion (TCI) dosing, creatinine clearance and allometric weight scaling
- Intrathecal Trastuzumab (HER2+ Breast Cancer CNS) → /apps/trastuzumab-csf-pk-simulator — Target-mediated drug disposition (TMDD) model for leptomeningeal carcinomatosis
- Losartan + EXP-3174 (Sinusoidal Gastric Emptying) → /apps/losartan-exp3174-gastric-emptying-pk — Unique oscillatory plasma concentration profiles post-oral dose
- Kovaltry Factor VIII (Hemophilia A) → /apps/kovaltry-factor-viii-popPK-simulator — Recombinant FVIII prophylaxis, lean body weight scaling
- Levamisole (Interspecies Allometric) → /apps/levamisole-pk-interspecies-allometric-2cm — Two-compartment allometric model across 8 species
- Tacrolimus CYP3A Genotype-Guided Dosing (Kidney Transplant) → /apps/tacrolimus-popPK-cyp3a-genotype-kidney-transplant
- Tacrolimus PopPK in Allo-HCT (CYP3A5 + Conditioning) → /apps/tacrolimus-population-pharmacokinetics-allo-hct-cyp3a5
- Tacrolimus IV Infusion (Pediatric HCT) → /apps/tacrolimus-iv-infusion-pediatric-hct-popPK
- Rucaparib PARP Inhibitor PK/PD (Breast Cancer) → /apps/rucaparib-parp-inhibitor-pkpd
- Topo1-ADC PBPK-PD Simulator → /apps/topo1-adc-pbpk-pd-simulator — PBPK-PD model for topoisomerase I-targeting antibody-drug conjugates including sacituzumab govitecan (Trodelvy, anti-Trop-2) and trastuzumab deruxtecan (Enhertu, anti-HER2) with camptothecin-based payloads (SN-38, DXd)
- T-DXd (Enhertu) PBPK-PD ILD Risk Simulator → /apps/tdxd-sg-pbpk-pd-ild-risk-simulator — Interactive T-DXd PBPK-PD simulator predicting DXd lung exposure and interstitial lung disease (ILD) risk stratified by dose and age (Wang et al. 2025)